The U.S. National Institutes of Health lifted its ban on funding HIV and tuberculosis research projects in South Africa this week [1, 2, 3].
This decision restores access to critical grants for scientists tackling two of the region's most persistent health crises. The funding freeze had stalled essential biomedical advancements and disrupted long-term clinical studies in the country.
The ban was originally imposed by the Trump administration for political reasons [4, 5]. According to reports, the NIH stopped funding in January 2025 [6], while other records indicate a stop-work order was issued in February 2025 [2].
Researchers faced a funding gap that lasted between 17 [7] and 18 months [8]. This disruption resulted in an estimated financial loss of $450 million [7].
The NIH is the largest biomedical research funder in the world [1, 2]. Its return to South Africa allows local institutions to resume the pursuit of new treatments and preventative measures for HIV and TB, diseases that continue to place a heavy burden on the South African healthcare system.
The restoration of these grants marks a shift back toward international scientific cooperation. South African research institutions had been operating under significant constraints since the freeze began early last year [6, 2].
“The world's largest biomedical research funder resumes grants for critical HIV and TB projects.”
The resumption of NIH funding signals a decoupling of scientific research from political disputes between the U.S. and South Africa. Because HIV and TB research requires longitudinal data and consistent funding to be effective, the 17-to-18-month gap may have created permanent data voids in certain studies, though the restoration prevents a total collapse of these critical public health initiatives.
